other material
confidence high
sentiment positive
materiality 0.90
Zipalertinib+chemo meets primary endpoint in Phase 3 REZILIENT3: PFS 14.5 vs 8.5 mo, HR 0.50
Cullinan Therapeutics, Inc.
- Median PFS 14.5 vs 8.5 months (HR 0.50; 95% CI 0.34-0.73; P=0.00015) in first-line EGFR ex20ins NSCLC.
- ORR 65.0% vs 40.3% (P<0.0001); median duration of response 14.2 vs 9.9 months.
- Interim OS HR 0.72 (95% CI 0.42-1.23) at 30% maturity; follow-up ongoing.
- Safety: Grade ≥3 AEs 87.1% vs 54.4%, mostly manageable hematologic; no new signals.